RxDoctor Payments DataLook up a doctor →

Natasha Mesinkovska

Procedural Dermatology · Mission Viejo, CANPI 1346415437

Payments from drug & device makers

$4,021,458in general payments, 2019–2025

Across 771 payments — averaging $5215.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1.3M
  • Eli Lilly$666K
  • AbbVie$600K
  • Sun Pharmaceutical Industries Inc.$495K
  • Novartis$319K
  • Lilly USA, LLC$215K
  • plus $420K from 14 others
$30,696in research payments, 2019–2025

Across 19 payments — averaging $1615.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$29K
  • Eli Lilly$2K

What the payments were for

  • Consulting fees$197,61240%
  • Speaking & faculty fees$245,72549%
  • Travel & lodging$49,73510%
  • Food & beverage$5,8171%
  • Education$500%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,021,458 in reported general payments places this provider in the 95th percentile of 108 procedural dermatology providers in California.

See all procedural dermatology providers in California

Medicare billing

Part B allowed, 2024
$139,758
Medicare patients
204
Services billed
1,704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OlumiantBaricitinib25$100,927
OpzeluraRuxolitinib Phosphate14$25,817
Minoxidil309$3,438
Hydroxychloroquine Sulfate50$2,998
Clobetasol Propionate48$1,500
Ketoconazole94$1,263
Doxycycline Monohydrate18$745
Fluocinonide20$687
ValacyclovirValacyclovir Hcl20$529
Fluconazole24$389
MethotrexateMethotrexate Sodium14$360
Triamcinolone Acetonide20$347
Finasteride18$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlumiant$215,094$100,92725 claims
Incyte CorporationOpzelura$7,850$25,81714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 108 procedural dermatology providers in California.

Other procedural dermatology in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →